Detecting metastatic melanoma early and accurately is critical for choosing the right treatment path and improving outcomes. Understanding who needs testing, what methods doctors use to find cancer spread, and how patients qualify for advanced therapies can help patients and their families navigate this challenging diagnosis with greater confidence.

Introduction: Who Should Undergo Diagnostics

Metastatic melanoma occurs when this aggressive form of skin cancer spreads beyond its original location to other parts of the body. Knowing when to seek diagnostic testing can make a significant difference in treatment outcomes. Anyone who has been previously diagnosed with melanoma should remain vigilant about follow-up care, as the cancer can return or spread even after successful initial treatment.^[1]

People who notice unusual changes in their skin should seek medical attention promptly. This is especially important for those who have fair skin, light-colored hair, blue eyes, or a family history of melanoma. Warning signs that warrant immediate diagnostic evaluation include new lumps under the skin, swollen or painful lymph nodes, persistent cough or breathing difficulties, unexplained weight loss, ongoing fatigue, bone pain, or neurological symptoms like headaches and seizures.^[2][5]

The ABCDE rule helps people identify suspicious skin changes that require professional evaluation. This rule examines five key features: Asymmetry (one half doesn’t match the other), Border (edges are irregular), Color (multiple or uneven colors), Diameter (larger than a pencil eraser tip), and Evolving (the spot is new or changing in size, shape, or color). Not all melanomas follow this pattern, so any unusual or persistent skin changes should be reported to a doctor.^[4]

Those who have already been diagnosed with melanoma face different monitoring needs depending on their initial tumor characteristics. Patients with deeper primary melanomas, those measuring more than four millimeters in depth, or those with ulceration of the primary lesion carry higher risks of developing metastatic disease. These individuals typically require more intensive surveillance and diagnostic testing schedules.^[1]

Diagnostic Methods for Identifying Metastatic Melanoma

Initial Clinical Assessment

The diagnostic journey typically begins with a thorough conversation between the patient and their healthcare provider. Doctors need to understand the complete picture, including when symptoms first appeared, how the patient has been feeling overall, any previous melanoma diagnoses and treatments, family history of melanoma, history of tanning bed use, frequency of sunburns, and sunscreen habits. This comprehensive background helps guide the diagnostic approach.^[2]

A physical examination follows this discussion, during which the doctor carefully inspects the skin for suspicious growths or changes. They also check for enlarged or tender lymph nodes, which are small, bean-shaped glands located in the neck, armpits, and groin that can become swollen when cancer spreads. The doctor may also look for lumps under the skin or other physical signs that melanoma has traveled beyond its original site.^[2]

Biopsy Procedures

When a suspicious area is identified, a biopsy becomes necessary to confirm whether melanoma is present. A biopsy involves removing a sample of tissue for examination under a microscope. There are several types of biopsies that doctors may use, depending on the location and characteristics of the suspicious area.^[2]

A punch biopsy removes a round piece of skin, like a small cookie cutter taking a sample. An excisional biopsy takes out the entire growth along with some surrounding tissue. A shave biopsy attempts to remove the growth by shaving it off at the skin’s surface. The choice of biopsy method depends on factors like the size and location of the suspicious area and how deep the doctor suspects the melanoma extends.^[2]

When examining the biopsy sample, a pathologist looks at how thick the melanoma is. Tumor thickness is one of the most important factors in predicting whether the cancer will spread. Generally speaking, thicker tumors carry a higher risk of metastasis. This information helps doctors determine what additional diagnostic tests are needed and what treatment approach might be most appropriate.^[2]

Lymph Node Evaluation

Because melanoma often spreads first to nearby lymph nodes before traveling to distant organs, evaluating these structures is a critical part of diagnosis. When lymph nodes feel enlarged during physical examination, doctors may perform a fine needle aspiration, which uses a thin needle to remove a sample of cells from the node. This simple procedure can quickly reveal whether cancer cells are present.^[2]

For patients with melanoma that appears to be at higher risk of spreading, a procedure called sentinel lymph node biopsy may be recommended. This technique identifies the first lymph node that drains the area where the melanoma started. If cancer cells are going to spread through the lymphatic system, they will likely show up in this sentinel node first. The procedure involves injecting a special dye or radioactive substance near the melanoma site, then tracking where it travels to identify which lymph node to test.^[1]

Blood Tests

While no single blood test can definitively diagnose metastatic melanoma, blood work provides valuable information about overall health and potential cancer spread. Doctors typically order a complete chemistry panel to assess how well major organs are functioning. Particular attention goes to liver and kidney function tests, as these organs are common sites where melanoma can spread.^[1]

The lactate dehydrogenase (LDH) test measures an enzyme that increases when tissue is damaged. Elevated LDH levels can indicate that melanoma has spread to distant sites, though this test alone cannot determine the specific location of metastases. High LDH levels are associated with more advanced disease and can affect treatment decisions and prognosis predictions.^[7]

Imaging Studies

Once melanoma is confirmed or strongly suspected, imaging tests help determine whether and where the cancer has spread. These tests create pictures of the inside of the body, allowing doctors to spot tumors in organs and tissues that cannot be seen or felt during a physical exam. The choice of imaging depends on the individual situation and what the doctor is looking for.^[2]

A chest X-ray uses low-dose radiation to create images of the lungs and chest cavity. Because the lungs are a common site for melanoma metastasis, this relatively simple and quick test is often one of the first imaging studies performed. However, chest X-rays can miss small tumors, so more detailed imaging may be needed if there is high suspicion of lung involvement.^[2]

Computed tomography (CT) scans use multiple X-ray images taken from different angles and combine them with computer processing to create detailed cross-sectional views of the body. CT scans can reveal melanoma that has spread to the lungs, liver, brain, or other organs. They are more sensitive than regular X-rays and can detect smaller tumors. Patients typically receive a contrast dye before the scan to make organs and blood vessels show up more clearly in the images.^[2]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves instead of radiation to create detailed pictures of organs and soft tissues. MRI is particularly useful for examining the brain and spinal cord, as it provides excellent detail of these structures. This test can show blood flow patterns and help locate cancer growths with great precision. Because melanoma can spread to the brain, MRI is often included in staging evaluations for patients with more advanced disease.^[2]

Positron emission tomography (PET) scans work differently from other imaging tests. Before the scan, patients receive an injection of a small amount of radioactive material, usually attached to a form of sugar. Cancer cells, which tend to use sugar more actively than normal cells, absorb more of this radioactive tracer. The PET scanner then detects this radiation and creates images showing where the radioactive material has accumulated. This can reveal cancer spread throughout the body in a single test. Sometimes PET scans are combined with CT scans in a single session to provide both functional and structural information.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials offer access to cutting-edge treatments that may not yet be widely available. However, joining a clinical trial requires meeting specific criteria, and diagnostic testing plays a central role in determining eligibility. Understanding what tests are needed and why can help patients prepare for potential trial enrollment while working with their healthcare team.^[6]

Biomarker and Genetic Testing

Modern melanoma treatment has been revolutionized by therapies that target specific genetic changes within cancer cells. Before enrolling in many clinical trials, especially those testing targeted therapies, patients must undergo genetic testing of their tumor tissue. This testing looks for specific mutations, or changes, in the cancer cell’s DNA that might make the tumor vulnerable to particular drugs.^[11]

The BRAF mutation is one of the most important genetic markers in melanoma. Approximately half of all melanomas carry mutations in the BRAF gene, which causes cells to grow and divide uncontrollably. Clinical trials testing BRAF inhibitors, either alone or in combination with MEK inhibitors, require confirmation that the patient’s tumor has this specific mutation. The test is typically performed on tissue from the original melanoma biopsy or from a more recent biopsy if the cancer has spread.^[8]

Some melanomas carry mutations in other genes, such as C-KIT, which can also be targeted with specific drugs. Comprehensive genetic testing helps match patients to clinical trials testing therapies designed for their tumor’s particular genetic profile. Without this testing, patients might be assigned to treatments unlikely to work for their specific type of melanoma.^[8]

Staging and Disease Assessment

Clinical trials typically enroll patients at specific disease stages, so accurate staging through diagnostic testing is essential for determining eligibility. The American Joint Committee on Cancer (AJCC) staging system is the standard framework used to classify melanoma. This system considers the thickness of the primary tumor, whether it has ulceration, whether lymph nodes contain cancer, and whether distant metastases are present.^[6]

For stage IV melanoma trials, which focus on cancer that has spread to distant parts of the body, imaging studies must clearly document the location and extent of metastatic disease. Some trials may specifically seek patients whose melanoma has spread to certain organs, such as the brain or liver, while others may exclude patients with brain metastases due to the complexity of treating cancer in that location. Complete imaging with CT and sometimes MRI scans helps determine whether a patient’s disease pattern matches trial requirements.^[6]

Performance Status and Organ Function

Beyond confirming melanoma diagnosis and genetic profile, clinical trials require documentation that patients are healthy enough to tolerate experimental treatments. Blood tests measuring liver function, kidney function, and blood cell counts are standard requirements. These tests ensure that vital organs can process and eliminate the study drugs and that the patient’s overall health won’t be compromised by treatment side effects.^[1]

Doctors assess what is called performance status, which measures how well patients can carry out daily activities. While this isn’t a test in the traditional sense, it is a standardized evaluation that affects trial eligibility. Patients who can care for themselves and remain active are more likely to qualify for trials than those who require significant assistance or spend much of their time in bed.^[1]

Baseline and Monitoring Assessments

Once enrolled in a clinical trial, patients undergo regular diagnostic testing to monitor how the treatment is working. Baseline imaging establishes a reference point, documenting the size and location of all detectable tumors before treatment begins. Follow-up imaging at predetermined intervals allows researchers to measure whether tumors are shrinking, staying stable, or growing. These measurements determine treatment effectiveness and guide decisions about continuing, modifying, or stopping the experimental therapy.^[12]

Blood tests are also repeated regularly throughout clinical trial participation. These monitor for treatment side effects and track certain markers that may indicate disease activity. For example, lactate dehydrogenase levels may be followed over time, with increasing levels potentially signaling disease progression even before it becomes visible on imaging studies.^[7]